Press Releases

Company to Report On Science And Progress Of DCVax-Direct Trial At World’s Largest Cancer Conference BETHESDA, Md., April 22, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its... Read More

Major Production Increase Being Undertaken To Meet Growing Demand BETHESDA, Md., April 15, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last... Read More

Funding Will Accelerate Expansion of European Manufacturing BETHESDA, Md., April 10, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on April 9, 2014, it entered into an agreement with a single institutional investor for a registered direct placement of up to $32 million. The Stock Purchase Agreement provides... Read More

Company Corrects His False Claims About Annual Report and Phase III Trial BETHESDA, Md., April 7, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein’s latest, sensationalized headline claims about the Company’s annual report and Phase III trial are once again factually wrong and... Read More

Company Reports Phase III Trial Progress, Positive Regulatory and ASCO Decisions; Feuerstein Falsely Claims Opposite of Positive Trial Information Announced by NW Bio BETHESDA, Md., March 28, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday,... Read More